比较β3-激动剂和抗肌糖药在膀过活的疗效和不良影响:一个网络和组件网络的元分析
Wenlin Huang1, Xueqin Zheng2, Jinyang Luo3
1Department of Urology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China.
European journal of clinical pharmacology
|June 7, 2025
概括
维贝格龙和米拉贝格龙有效治疗过度活动膀 (OAB) 症状,如排尿频率和失禁. 组合疗法通常提供优越的症状控制与单一疗法相比,短期的OAB管理.
科学领域:
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 基于证据的医学基于证据的医学.
背景情况:
- 过度活跃的膀 (OAB) 显著影响生活质量.
- β3-上腺体受体激动剂为OAB提供了一个治疗选择.
- 将这些药物及其组合进行比较对于最佳的治疗策略至关重要.
研究的目的:
- 为了比较β3-上腺素受体激动剂 (vibegron,mirabegron) 在OAB治疗中的疗效和安全性.
- 为了评估单一疗法与用抗肌类药物的联合疗法.
- 使用网络元分析 (NMA) 和组件网络元分析 (cNMA) 进行可靠的比较.
主要方法:
- 对OAB患者进行II/III期RCT (2010年1月至2024年6月) 的系统搜索.
- 包括对vibegron和mirabegron的试验 (单疗/组合).
- 分析使用NMA和cNMA的初级结局 (流动频率,紧迫性,失禁,空白体积) 和二次结局 (不良事件).
主要成果:
- 与mirabegron和antimuscarinic相比,Vibegron在减少排尿频率方面表现出更高的有效性.
- 组合疗法通常比单一疗法更能改善急性情节和失禁.
- 较高剂量和组合疗法与口腔干燥和便秘的风险增加有关,整体不良事件没有显著差异.
结论:
- β3-激动剂,特别是vibegron,在控制OAB症状方面是有效的,包括排尿频率和失禁.
- 组合疗法在短期控制OAB症状方面似乎比单一疗法更有效.
- NMA和cNMA为治疗疗效和潜在相互作用提供了宝贵的见解.
相关概念视频
Cholinergic Antagonists: Pharmacokinetics
568
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
568
Cholinergic Antagonists: Pharmacological Actions
1.3K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.3K
Cholinergic Antagonists: Therapeutic Uses
892
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
892
Antiasthma Drugs: Muscarinic Receptor Antagonists
479
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
479
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.6K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.0K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.0K


